TG Therapeutics | TGTX - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.63B 54M 2026-06
Alaunos Therapeutics USD 447K 138K 2026-03
Amgen USD 1.58B 354M 2026-03
Ardelyx USD 102.27M 26.35M 2026-03
Arrowhead Research USD 41.74M 4.28M 2026-03
Bayer EUR 3.7B 356M 2026-03
Biogen USD 709.7M 155.4M 2026-06
Corcept Therapeutics USD 156.9M 28.85M 2026-06
Curis USD 1.34M 3.45M 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
J&J USD 6.42B 381M 2026-06
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Novartis USD 3.24B 101M 2026-06
Novavax USD 25.53M 1.34M 2025-12
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
TG Therapeutics USD 73.14M 22.42M 2026-03
Verastem USD 24.44M 12.17M 2025-12
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03